Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCLAIM phase 3 study of romiplostim for chemotherapy-induced thrombocytopenia
2023-507149-27-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) comparing Nplate plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoint: Incidence of thrombocytopenia-induced chemotherapy dose delay or reduction. Planned start Apr 2024; status: authorised.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on 2023-507149-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507149-27-00.